Increased Risk of Atrial Fibrillation in the Early Period after Herpes Zoster Infection: a Nationwide Population-based Case-control Study

Myung-Jin Cha, Hyun-Min Seo, Eue-Keun Choi, Ji Hyun Lee, Kyungdo Han, So-Ryoung Lee, Woo-Hyun Lim, Young Min Park, and Seil Oh

1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
2Department of Dermatology, Hanyang University Guri Hospital, Guri, Korea
3Department of Dermatology, The Catholic University of Korea, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
4Department of Biostatistics, The Catholic University of Korea College of Medicine, Seoul, Korea
5Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
6Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

ABSTRACT

Background: Herpes zoster (HZ) is a chronic inflammatory disease that could result in autonomic dysfunction, often leading to atrial fibrillation (AF).

Methods: From the Korean National Health Insurance Service database of 738,559 subjects, patients newly diagnosed with HZ (n = 30,685) between 2004 and 2011, with no history of HZ or AF were identified. For the non-HZ control group, 122,740 age- and sex-matched subjects were selected. AF development in the first two-years following HZ diagnosis, and during the overall follow-up period were compared among severe (requiring hospitalization, n = 2,213), mild (n = 28,472), and non-HZ (n = 122,740) groups.

Results: There were 2,204 (1.4%) patients diagnosed with AF during follow-up, and 825 (0.5%) were diagnosed within the first two years after HZ. The severe HZ group showed higher rates of AF development (6.4 per 1,000 patient-years [PTPY]) compared to mild-HZ group (2.9 PTPY) and non-HZ group (2.7 PTPY). The risk of developing AF was higher in the first two-years after HZ diagnosis in the severe HZ group (10.6 PTPY vs. 2.7 PTPY in mild-HZ group and 2.6 PTPY in non-HZ group).

Conclusion: Severe HZ that requires hospitalization shows an increased risk of incident AF, and the risk is higher in the first two-years following HZ diagnosis.

Keywords: Atrial Fibrillation; Herpes Zoster; Inflammation; Autonomic Dysfunction

INTRODUCTION

The incidence of atrial fibrillation (AF), the most common type of clinically significant cardiac arrhythmia, has increased over the last decade.1 AF is associated with high medical costs, as well as an increased risk of ischemic stroke and death.2 Although the precise mechanisms involved in AF are not well understood, a growing body of evidence indicates that inflammation...
Herpes zoster (HZ) is caused by reactivation of the latent varicella-zoster virus (VZV) in the cranial nerve, dorsal root, or autonomic ganglia with spread of the virus along the sensory nerve to the dermatome producing radiculoneuritis and cutaneous manifestations. Unvaccinated persons over 85 years of age have a 50% risk of developing HZ. HZ may result in serious neurologic or inflammatory sequelae and severe cases often require hospitalization (up to 3% of HZ cases). The neurologic sequelae of HZ is well-known, and can result in autonomic dysfunction. The vagus nerve or its ganglia can be involved in HZ, resulting in dysphagia, nausea, vomiting, gastric upset, or cardiac irregularities.

According to the pathogenesis of the two diseases, AF can occur as a complication of HZ, but the relationship between AF and HZ has not been studied widely. We hypothesized that HZ may be associated with AF development.

METHODS

Study population
From the Korean National Health Insurance Service (NHIS) database, we used a random multistage representative sample of 1,034,777 people. Consequently, a total of 738,559 subjects were selected for analysis after patients less than 20 years of age and patients who had been treated for either AF or HZ during the screening period (2002–2004) were excluded. Newly diagnosed HZ patients (n = 30,685) were identified using health insurance claims data from 2005 to 2011. We defined the index date on which each patient was first diagnosed with HZ as the index date. On the same index date, four age- and sex-matched non-HZ control subjects were selected for analysis after patients less than 20 years of age and patients who had been treated for either AF or HZ during the screening period (2002–2004) were excluded.

Database
Records from the NHIS database included patients’ sociodemographic information, their use of inpatient and outpatient services, and pharmacy dispensing claims. The majority (97.1%) of the Korean population (approximately 50 million people) is covered by the mandatory NHIS. Diagnoses were confirmed using the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes. In the present study, multistage sampling was performed, and we used a random sample of one million people selected from the NHIS database. The staff of the NHIS confirmed that the study cohort was a representative sample of the general Korean population for the period 2002 to 2013.

Definition
Instances of newly diagnosed AF (I480–I484, I489) identified during follow-up were analyzed as in our previous studies and the HZ and non-HZ group were compared. Patients who were diagnosed with mitral stenosis (I050, I052, and I059) or those who had mechanical heart valves (Z952–Z954) implanted from 2002 to 2013 were excluded from the analysis.

The presence and severity of HZ was determined on the basis of diagnostic and procedure codes recorded during the study period from 2005 to 2011. A HZ patient was identified by...
the diagnostic code for HZ (B02) and received either oral anti-viral medication for at least five days, or an anti-viral injection more than once. Hospitalization due to HZ was obtained from the database. A newly diagnosed HZ patient requiring simultaneous hospitalization was defined as a severe HZ case. The remaining HZ patients, who were treated as outpatients, were considered mild HZ cases. The epidemiology of HZ in Korea has been previously reported using NHIS database records.16

**Statistical analysis**

Baseline characteristics are presented as mean and standard deviation, or numbers and percentages. The differences between continuous values were assessed using an unpaired two-tailed t-test for normally distributed continuous variables and a Mann-Whitney rank-sum test for skewed variables. The \( \chi^2 \) test was used for the comparison of nominal variables. We used risk set sampling for selection of the age- and sex-matched control subjects. Incidence rates were described as the number of events per 1,000 patient-years (PTPY). Hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. Comparison of cumulative event rates between HZ and non-HZ groups was based on Kaplan-Meier censoring estimates and performed with the log-rank test. Crude risks were analyzed in the overall cohort, and adjusted results were subsequently calculated with the multivariable Cox regression analyses. Subgroup analyses of multiple cardiovascular risk factors were subsequently performed. The level of statistical significance was set at \( P < 0.05 \), and all statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) and SPSS (IBM® SPSS® Statistics version 22; IBM Corp., Armonk, NY, USA).

**Ethics statement**

The database is open to any researcher whose study protocols have been approved by the official review committee. This study was approved by Institutional Review Board of Seoul National University Hospital, Seoul, Korea (approval No. 1607-032-773).

**RESULTS**

**Baseline characteristics**

A total of 153,425 adults (aged over 20) with no history of AF or HZ were analyzed. The baseline characteristics and demographic features of patients according to HZ severity are described in Table 1. The mean age of the total study population was 53.8 ± 15.2 years, and 60.1% of the patients were female. The HZ group had significantly more comorbidities than the non-HZ group, and the severe HZ group had the highest CHA\(_2\)DS\(_2\)-VASc score of all three groups. A total of 2,204 (1.4%) patients were diagnosed with new AF, and among them 825 (0.5%) patients were diagnosed within two years of their index (diagnosis) date.

**Relative risk of AF development according to HZ severity**

The HZ group showed a higher incidence of AF than the non-HZ group. The number of events, calculated incidence rates, and unadjusted and adjusted HRs for AF and stroke according to HZ severity are described in Table 2. Those with severe HZ were at significantly higher risk of developing AF (n = 66, 6.4 per 1,000 PTPY) compared to those with mild HZ (n = 384, 2.9 PTPY) and the non-HZ group (n = 1,732, 2.7 PTPY) (Fig. 1A). In a landmark analysis (Fig. 1B), the risk of developing AF was significantly greater for severe HZ cases in the two-year period following HZ diagnosis; however, after the two-year period, the relative risk of developing AF did not differ significantly in the three groups.
We re-grouped the patients into two groups: a severe HZ group and a control group (mild HZ plus non-HZ patients). We did this because the overall incidence of AF was not significantly different for mild HZ patients and the non-HZ group. The baseline characteristics of the two groups are described in Supplementary Table 1. The overall cumulative incidence of AF in the severe HZ group and in the control group within the two-year period following HZ diagnosis, was 3.0% and 1.4%, respectively (HR, 2.30; 95% CI, 1.81–2.95; \( P < 0.001 \)). Analysis after adjustment for CHA\(^2\)DS\(^2\)-VASc score and socio-economic status (income status and residence) showed the same results as the original analysis (HR, 1.46; 95% CI, 1.14–1.87; \( P = 0.003 \) in the severe HZ group). The detailed data is shown in Supplementary Table 2 and Supplementary Table 1.

#### Table 1. Baseline characteristics of patients with or without HZ

| Variables                        | Total (n = 30,685) | Severe HZ (n = 2,213) | Mild HZ (n = 28,472) | Non-HZ (n = 122,740) | P value (HZ vs. non-HZ) |
|----------------------------------|--------------------|-----------------------|----------------------|----------------------|-------------------------|
| Age, yr                          | 53.8 ± 15.2        | 60.6 ± 15.3           | 53.3 ± 15.0          | 53.9 ± 15.2          | 0.507                   |
| > 65                             | 8,100 (26.4)       | 990 (44.7)            | 7,110 (25.0)         | 32,397 (26.4)        | 0.499                   |
| ≥ 75                             | 2,557 (8.3)        | 418 (18.9)            | 1,795 (6.3)          | 10,292 (8.3)         | 0.503                   |
| Men                              | 12,232 (39.9)      | 839 (37.9)            | 11,393 (40.0)        | 48,928 (39.9)        | 0.503                   |
| Hypertension                     | 9,053 (29.5)       | 992 (44.8)            | 8,061 (28.3)         | 30,689 (25.0)        | < 0.001                 |
| Diabetes                         | 3,219 (10.5)       | 421 (18.9)            | 2,795 (9.8)          | 10,229 (8.3)         | < 0.001                 |
| Dyslipidemia                     | 7,436 (24.2)       | 751 (33.9)            | 6,685 (23.5)         | 21,587 (17.6)        | < 0.001                 |
| Heart failure                    | 780 (2.5)          | 132 (6.0)             | 648 (2.3)            | 2,527 (2.0)          | < 0.001                 |
| Chronic obstructive pulmonary disease | 2,914 (9.5)   | 387 (17.5)            | 2,527 (8.3)          | 8,506 (6.9)          | < 0.001                 |
| Previous ischemic heart disease  | 1,963 (6.4)        | 317 (14.3)            | 1,646 (5.8)          | 5,685 (4.6)          | < 0.001                 |
| Previous stroke/TIA              | 1,123 (3.7)        | 209 (9.4)             | 914 (3.2)            | 3,760 (3.1)          | < 0.001                 |
| Urban residents                  | 14,756 (48.2)      | 904 (40.8)            | 13,852 (48.7)        | 57,110 (46.5)        | < 0.001                 |
| Low income level                 | 4,565 (14.9)       | 339 (15.3)            | 4,226 (14.8)         | 21,413 (19.1)        | < 0.001                 |
| Follow-up duration, yr           | 4.7 ± 1.8          | 4.7 ± 2.0             | 4.7 ± 1.8            | 5.2 ± 1.7            | < 0.001                 |
| AF development during follow-up  | 450 (1.5)          | 66 (3.0)              | 384 (1.3)            | 1,732 (1.4)          | 0.231                   |
| AF development within 2 yr       | 198 (0.6)          | 46 (2.1)              | 152 (0.5)            | 627 (0.5)            | 0.002                   |

HZ = herpes zoster, TIA = transient ischemic attack, AF = atrial fibrillation.

#### Table 2. Association between HZ severity and AF

| AF development                  | No. of events | Incidence rate\(^a\) | Unadjusted HR (95% CI) | P value | Multivariate adjusted HR (95% CI) | P value |
|---------------------------------|---------------|----------------------|------------------------|---------|----------------------------------|---------|
| Overall                         |               |                      |                        |         |                                  |         |
| Non-HZ                          | 1,732/122,740 | 2.7                  | 1.00 (reference)       |         | 1.00 (reference)                 |         |
| Mild HZ                         | 384/28,472    | 2.9                  | 1.05 (0.94–1.18)       | 0.352   | 1.03 (0.92–1.15)                 | 0.634   |
| Severe HZ                       | 66/2,213      | 6.4                  | 2.33 (1.82–2.98)       | < 0.001 | 1.47 (1.15–1.88)                 | 0.002   |
| Within 2 yr                     |               |                      |                        |         |                                  |         |
| Non-HZ                          | 627/122,740   | 2.6                  | 1.00 (reference)       |         | 1.00 (reference)                 |         |
| Mild HZ                         | 152/28,472    | 2.7                  | 1.04 (0.87–1.24)       | 0.375   | 1.00 (0.84–1.19)                 | 0.990   |
| Severe HZ                       | 46/2,213      | 10.6                 | 4.07 (3.02–5.50)       | < 0.001 | 2.33 (1.72–3.15)                 | < 0.001 |
| After 2 yr                      |               |                      |                        |         |                                  |         |
| Non-HZ                          | 1,105/122,117 | 2.8                  | 1.00 (reference)       |         | 1.00 (reference)                 |         |
| Mild HZ                         | 232/23,320    | 3.0                  | 1.06 (0.92–1.22)       | 0.438   | 1.04 (0.90–1.20)                 | 0.591   |
| Severe HZ                       | 20/2,167      | 3.3                  | 1.17 (0.75–1.82)       | 0.495   | 0.79 (0.50–1.22)                 | 0.286   |

HZ = herpes zoster, AF = atrial fibrillation, HR = hazard ratio, CI = confidence interval.

\(^a\)Incidence rates were calculated per 1,000 patient-years, within the population who were over 20 years old and not previously diagnosed with AF; \(^b\)Multivariate adjusted hazard ratios were calculated by Cox regression models, including income level, resident area, CHA\(^2\)DS\(^2\)-VASc score as covariates.

**Severe HZ vs. mild HZ or non-HZ patients**

We re-grouped the patients into two groups: a severe HZ group and a control group (mild HZ plus non-HZ patients). We did this because the overall incidence of AF was not significantly different for mild HZ patients and the non-HZ group. The baseline characteristics of the two groups are described in Supplementary Table 1. The overall cumulative incidence of AF in the severe HZ group and in the control group within the two-year period following HZ diagnosis, was 3.0% and 1.4%, respectively (HR, 2.30; 95% CI, 1.81–2.95; \( P < 0.001 \)). Analysis after adjustment for CHA\(^2\)DS\(^2\)-VASc score and socio-economic status (income status and residence) showed the same results as the original analysis (HR, 1.46; 95% CI, 1.14–1.87; \( P = 0.003 \) in the severe HZ group). The detailed data is shown in Supplementary Table 2 and...
Supplementary Fig. 2. The risk of AF development was more pronounced in the two-year period following HZ diagnosis in the severe HZ group.

**Subgroup analyses**

Formal testing for interactions showed that the overall AF development rates in the severe HZ group and the control group were consistent across multiple subgroups (Fig. 2). Across the two subgroups defined by CHA\textsuperscript{2}DS\textsuperscript{2}-VASc (cut-off score of 3), the risk of AF development was significantly higher in the severe HZ group (Supplementary Tables 3 and 4). The relationship between AF and HZ was strong in the first two years after diagnosis.

**Propensity score matched analysis**

Although age and sex were matched between HZ and non-HZ group, the patients with HZ had more comorbidities. Therefore, we performed 1:2 propensity score matching, and the demographic features of matched population is demonstrated in Supplementary Table 5. A comorbidity and socioeconomic status (hypertension, diabetes, dyslipidemia, previous stroke/transient ischemic attack [TIA], heart failure, end-stage renal disease, chronic obstructive pulmonary disease, previous ischemic heart disease, low income level, and urban residence) in addition to age and sex between HZ and non-HZ group were matched. Kaplan-Meier curve from the propensity score matched cohort according to HZ severity are presented in Supplementary Table 6 and Supplementary Fig. 3. In accordance with overall cohort analysis, the risk of AF development was more obvious 2 years after HZ diagnosis, while the relative risk of AF after 2 years from index date among three severity groups were not significantly different.

**DISCUSSION**

In our nationwide case-control cohort study, we found an association between HZ and the development of AF. The main finding was that patients with severe HZ requiring hospitalization have an increased risk of incident AF within the two-year period following HZ diagnosis.
Inflammatory process is a well-established pathogenic process in exacerbated atherosclerosis. Many studies have supported a close link between AF and inflammatory processes. A high incidence of AF in patients after cardiac surgery, a well-known state of intense inflammatory process was reported. Furthermore, a high serum C-reactive protein level has been reported to be related to AF development, increased AF burden, and higher recurrence rates after catheter ablation and electrical cardioversion for AF. Previous studies have demonstrated that a higher interleukin (IL)-6 level is associated with a higher risk of incident AF following coronary artery bypass graft surgery and a higher AF recurrence rate following cardioversion. The nationwide population based study on Herpes simplex infection reported that the viral inflammatory disease could be associated with an increased risk of AF. Bacterial infections such as Helicobacter pylori and Chlamydia pneumoniae have also shown an association with the occurrence of AF. However, there has been no population-based epidemiology study on the association between VZV and AF. Given that HZ involves a chronic latent inflammation, there is a strong possibility that it is associated with AF.

| Subgroup                | Total No. of patients | Incidence rate | HR (95% CI) | P value |
|-------------------------|-----------------------|----------------|-------------|---------|
|                         |                       | Non-HZ | Severe HZ |             |         |
| All                     | 153,425               | 2.70   | 6.40      | 2.31 (1.81–2.95) |         |
| Sex                     |                       |        |           |             |         |
| Male                    | 61,160                | 3.17   | 7.39      | 2.32 (1.60–3.35) | < 0.001 |
| Female                  | 92,265                | 2.46   | 5.75      | 2.33 (1.68–3.33) |         |
| Age                     |                       |        |           |             |         |
| ≥ 65                    | 40,497                | 6.80   | 11.14     | 1.63 (1.23–2.16) | < 0.001 |
| < 65                    | 112,928               | 1.34   | 2.59      | 1.93 (1.16–3.22) |         |
| Diabetes                |                       |        |           |             |         |
| Yes                     | 13,495                | 5.80   | 11.31     | 1.94 (1.25–3.01) | < 0.001 |
| No                      | 139,930               | 2.47   | 5.29      | 2.13 (1.59–2.87) |         |
| Hypertension            |                       |        |           |             |         |
| Yes                     | 39,742                | 6.15   | 10.25     | 1.65 (1.23–2.22) | < 0.001 |
| No                      | 113,683               | 1.63   | 3.41      | 2.09 (1.34–3.27) |         |
| Dyslipidemia            |                       |        |           |             |         |
| Yes                     | 29,023                | 5.27   | 9.16      | 1.72 (1.19–2.47) | < 0.001 |
| No                      | 124,402               | 2.22   | 5.08      | 2.29 (1.64–3.18) |         |
| Heart failure           |                       |        |           |             |         |
| Yes                     | 3,307                 | 15.67  | 26.43     | 1.68 (1.01–2.79) | < 0.001 |
| No                      | 150,118               | 2.48   | 5.13      | 2.06 (1.56–2.73) |         |
| Stroke history          |                       |        |           |             |         |
| Yes                     | 4,883                 | 9.19   | 14.71     | 1.57 (0.91–2.70) | < 0.001 |
| No                      | 148,542               | 2.55   | 5.53      | 2.17 (1.64–2.85) |         |
| Ischemic heart disease  |                       |        |           |             |         |
| Yes                     | 7,648                 | 11.49  | 14.14     | 1.21 (0.77–1.90) | < 0.001 |
| No                      | 145,777               | 2.33   | 5.14      | 2.21 (1.65–2.96) |         |
| Income level            |                       |        |           |             |         |
| Low                     | 27,978                | 3.23   | 5.95      | 1.84 (0.95–3.55) | 0.001   |
| Intermediate-high       | 125,447               | 2.64   | 6.44      | 2.44 (1.87–3.17) |         |
| Residence               |                       |        |           |             |         |
| Urban                   | 71,866                | 2.55   | 7.31      | 2.85 (1.99–4.07) | 0.006   |
| Rural                   | 81,559                | 2.92   | 5.72      | 1.96 (1.40–2.74) |         |

Fig. 2. Subgroup analyses for AF risk.
AF = atrial fibrillation, HZ = herpes zoster, HR = hazard ratio, CI = confidence interval.
The intrinsic cardiac autonomic nervous system plays a critical role in the initiation and maintenance of AF, and sympathovagal discharges are common triggers for paroxysmal AF. There are many ganglionic plexuses around the atria, which is markedly influenced by cholinergic as well as sympathetic innervation. Changes in autonomic tone before the onset of paroxysmal AF have been reported, suggesting autonomic dysfunction may lead to the development of AF. HZ can involve nerve ganglia, resulting in autonomic dysfunction. Alternatively, VZV reactivations may cause the neuritis of the sympathetic and autonomic ganglia. HZ is reported to affect the autonomic nervous system of the colon due to the centripetal spread of the virus from the dorsal ganglion. In addition, the vagus nerve or its ganglia can be involved in HZ, resulting in cardiac irregularities. The reactivation may involve multi-loci, including dermatome and symptomatic ganglia that innervate the heart, leading to cardiovascular disease. The immune response has been shown to play an important role in the ganglia during VZV reactivation. Unfortunately, we could not find direct evidence that HZ involves cardiac ganglionic plexuses. Based on the literary evidence cited above, we assumed that HZ might lead to AF development via cardiac autonomic nervous system involvement.

To our knowledge, this is the first report to prove an increased risk of developing AF in the early period after a particular infection. The development of AF shortly after an infection may be associated with HZ. In our cohort, about two percent of patients developed newly diagnosed AF within two years of HZ diagnosis, and this difference made the overall risk difference. AF can be asymptomatic and delayed diagnosis is common in real world clinical situations, thus the risk of incident AF may actually be higher within the short-term period following HZ diagnosis.

Because of the increasing incidence of AF and the ever-increasing public health burden it produces, significant efforts have been made recently in both risk factor identification and modifications for AF prevention. A number of traditional risk factors for AF have been identified, many of which are also associated with cardiovascular diseases, and the common preventive strategies focus on conventional modification of cardiovascular risk factors such as obesity, glucose control, blood pressure control, etc.

Furthermore, given that HZ is an inflammatory disease involving the nervous system, it can be prevented with vaccination. A significant proportion of AF cases could be prevented by HZ vaccination, and this has potential to dissipate the medical socio-economic burden.

One of the highlights of this study is the large comparison cohort stratified by age and gender. The effects of diabetes, hypertension, and hyperlipidemia on cardiovascular diseases were able to be adjusted according to the Cox proportional hazards. Subgroup analyses were performed to ensure the consistency of the results. However, several limitations of the present study remain. First, personal information such as smoking habits, physical activity, and body mass index were not available from this registry database. In addition, echocardiographic parameters, such as left atrial dimension and left ventricular ejection fraction, or electrocardiographic results were absent. Therefore, we were not able to control effectively for all potential confounders, although we have tried to adjust for important comorbidities in the Cox regression model. Second, HZ was diagnosed using ICD-10-CM codes and was not confirmed by molecular biological detection. The accuracy of HZ diagnosis could not be fully ascertained. Third, selection bias due to hospitalization might affect the detection rate of AF. Routine ECG screenings during hospitalization might increase...
the chance of detection of AF, so hospitalized severe HZ patients would have more chance to detect AF than non-hospitalized control group. However, we found that the incident AF occurred consistently during 2 years after diagnosed with HZ, and there is little chance to admit for 2 years due to HZ. Although there might be selection bias during early admission period in severe HZ patients, consistent occurrence of AF during 2 years of follow-up after HZ development would support our final conclusion. Lastly, while we reported a significant association between AF and HZ, these results were derived from an observational database. As we were not able to conclude whether HZ was the direct cause of the increased AF incidence, a further prospective and large-scale trial is necessary to confirm the findings of the present study.

Our results suggest that severe HZ requiring hospitalization is a possible risk factor for AF, and that AF incidence is greater for severe HZ patients in the two-year period following HZ diagnosis.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
Baseline characteristics of severe HZ group and control group

Click here to view

**Supplementary Table 2**
Unadjusted and adjusted HR for AF development in severe HZ or the control group

Click here to view

**Supplementary Table 3**
Unadjusted and adjusted HR for AF development in severe HZ according to CHA\textsubscript{2}DS\textsubscript{2}-VASc score ≤ 2

Click here to view

**Supplementary Table 4**
Unadjusted and adjusted HR for AF development in severe HZ according to CHA\textsubscript{2}DS\textsubscript{2}-VASc score ≥ 3

Click here to view

**Supplementary Table 5**
Patients characteristics of HZ and non-HZ group in 1:2 propensity matched population

Click here to view

**Supplementary Table 6**
Association between HZ severity and AF (1:2 propensity score matched population)

Click here to view
**Supplementary Fig. 1**
Study flow.

Click here to view

**Supplementary Fig. 2**
Overall AF development: severe HZ versus control group.

Click here to view

**Supplementary Fig. 3**
Overall AF development: severe HZ versus control group.

Click here to view

**REFERENCES**

1. Shin HW, Kim YN, Bae HJ, Lee HM, Cho HO, Cho YK, et al. Trends in oral anticoagulation therapy among Korean patients with atrial fibrillation: the KORean Atrial Fibrillation Investigation. *Korean Circ J* 2012;42(2):113-7.

2. Jung BC, Kim NH, Nam GB, Park HW, On YK, Lee YS, et al. The Korean Heart Rhythm Society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean Heart Rhythm Society. *Korean Circ J* 2015;45(1):9-19.

3. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. *J Am Coll Cardiol* 2012;60(22):2263-70.

4. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res* 2014;114(9):1500-15.

5. Ren Y, Zeng RX, Li JJ, Guo LH, He DY, Li Y, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction: a systematic review and meta-analysis. *Int J Cardiol* 2015;190:268-70.

6. Schauerte P, Scherlag BJ, Patterson E, Scherlag MA, Matsudaria K, Nakagawa H, et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. *J Cardiovasc Electrophysiol* 2001;12(55):592-9.

7. Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. *Clin Infect Dis* 2010;50(7):1000-5.

8. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. *BMJ Open* 2014;4(6):e004833.

9. Cohen JI. Herpes zoster. *N Engl J Med* 2013;369(18):1766-7.

10. Weaver SM, Kelly AP. Herpes zoster as a cause of neurogenic bladder. *Catis* 1982;29(6):611-2.

11. Lambert SB. Postherpetic neuralgia after herpes zoster vaccination. *JAMA* 2012;308(14):1427.

12. McCrory ML, Severson J, Tyring SK. Varicella zoster virus. *J Am Acad Dermatol* 1999;41(1):1-14.

13. Son MK, Lim NK, Cho MC, Park HY. Incidence and risk factors for atrial fibrillation in Korea: the National Health Insurance Service Database (2002-2010). *Korean Circ J* 2016;46(4):515-21.
14. Kang SH, Choi EK, Han KD, Lee SR, Lim WH, Cha MJ, et al. Underweight is a risk factor for atrial fibrillation: a nationwide population-based study. *Int J Cardiol* 2016;215:449-56. [PUBMED] [CROSSREF]

15. Lee SR, Choi EK, Rhee TM, Lee HJ, Lim WH, Kang SH, et al. Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: a nationwide population-based study. *Int J Cardiol* 2016;223:953-7. [PUBMED] [CROSSREF]

16. Kim YI, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. *J Korean Med Sci* 2014;29(12):1706-10. [PUBMED] [CROSSREF]

17. Ommon SR, Odel JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. *N Engl J Med* 1997;336(20):1429-34. [PUBMED] [CROSSREF]

18. Jacob KA, Buigjsrogge MP, Frencken JF, Ten Berg MJ, Suyker WJ, van Dijk D, et al. White blood cell count and new-onset atrial fibrillation after cardiac surgery. *Int J Cardiol* 2016;228:971-6. [PUBMED] [CROSSREF]

19. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? *Eur Heart J* 2006;27(2):136-49. [PUBMED] [CROSSREF]

20. Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G, et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. *Thromb Haemost* 2010;104(1):122-7. [PUBMED] [CROSSREF]

21. Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. *Scand J Clin Lab Invest* 2009;69(3):425-32. [PUBMED] [CROSSREF]

22. Chiang CH, Huang CC, Chan WL, Huang PH, Chen YC, Chen TJ, et al. Herpes simplex virus infection and risk of atrial fibrillation: a nationwide study. *Int J Cardiol* 2013;164(2):201-4. [PUBMED] [CROSSREF]

23. Andrew P, Montenero AS. Is there a link between atrial fibrillation and certain bacterial infections? *J Cardiovasc Med (Hagerstown)* 2007;8(12):990-6. [PUBMED] [CROSSREF]

24. Chen M, Yu L, Zhou X, Liu Q, Jiang H, Zhou S. Low-level vagus nerve stimulation: an important therapeutic option for atrial fibrillation treatment via modulating cardiac autonomic tone. *Int J Cardiol* 2015;199:437-8. [PUBMED] [CROSSREF]

25. Armour JA, Murphy DA, Yuan BX, Macdonald S, Hopkins DA. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. *Anat Rec* 1997;247(2):289-98. [PUBMED] [CROSSREF]

26. Choi EK, Shin MJ, Han S, Kim D, Hwang S, Sayfo S, et al.. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. *Circulation* 2010;121(24):2615-23. [PUBMED] [CROSSREF]

27. Edelman DA, Antaki F, Basson MD, Salwen WA, Gruber SA, Losanoff JE. Ogilvie syndrome and herpes zoster: case report and review of the literature. *J Emerg Med* 2010;39(5):696-700. [PUBMED] [CROSSREF]

28. Kang JH, Park YS, Park SY, Kim SB, Ko KP, Seo YH. Varicella seroprevalence among health care workers in Korea: validity of self-reported history and cost-effectiveness of prevaccination screening. *Am J Infect Control* 2014;42(6):885-7. [PUBMED] [CROSSREF]